aTyr Pharma, Inc. (ATYR)
NASDAQ: ATYR · Real-Time Price · USD
4.700
-0.020 (-0.42%)
At close: Aug 1, 2025, 4:00 PM
4.750
+0.050 (1.06%)
After-hours: Aug 1, 2025, 7:55 PM EDT

Company Description

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.

Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.

It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.

aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

aTyr Pharma, Inc.
aTyr Pharma logo
CountryUnited States
Founded2005
IPO DateMay 7, 2015
IndustryBiotechnology
SectorHealthcare
Employees65
CEOSanjay Shukla

Contact Details

Address:
10240 Sorrento Valley Road, Suite 300
San Diego, California 92121
United States
Phone858 731 8389
Websiteatyrpharma.com

Stock Details

Ticker SymbolATYR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001339970
CUSIP Number002120202
ISIN NumberUS0021202025
Employer ID20-3435077
SIC Code2836

Key Executives

NamePosition
Dr. Sanjay S. Shukla M.D., M.S.President, Chief Executive Officer and Director
Jill M. Broadfoot CPAChief Financial Officer
Nancy E. Denyes Krueger J.D.General Counsel and Corporate Secretary
Dr. Jayant Aphale MBA, Ph.D.Vice President of Technical Operations
Ashlee DunstonDirector of Investor Relations and Corporate Communications
Peter VilligerVice President of Corporate Development
Danielle CampbellVice President of Human Resource
Dalia R. Rayes M.B.A.Head of Commercial, Global Efzofitimod Franchise
Dr. Leslie Nangle Ph.D.Vice President of Research

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13GFiling
Jul 17, 2025SCHEDULE 13GFiling
May 15, 2025SCHEDULE 13G/AFiling
May 7, 202510-QQuarterly Report
May 7, 20258-KCurrent Report
May 6, 20258-KCurrent Report
Mar 19, 2025ARSFiling
Mar 19, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 19, 2025DEF 14AOther definitive proxy statements
Mar 13, 202510-KAnnual Report